Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 3, 2007, Pages 1228-1236

  Hamrah, Pedram ^a   Yamagami, Satoru ^a,c   Liu, Ying ^a   Zhang, Qiang ^a   Vora, Sudhir S ^a   Lu, Bao ^b   Gerard, Craig J ^b   Dana, M Reza ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOSPORIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; CC CHEMOKINE RECEPTOR 1; CHEMOKINE RECEPTOR; IMMUNOSUPPRESSIVE AGENT; RANTES; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DELAYED HYPERSENSITIVITY; ENZYME ASSAY; GENE DELETION; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HOST; KNOCKOUT GENE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STRAIN DIFFERENCE; SURVIVAL RATE; WILD TYPE; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CORNEA; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; IMMUNOLOGY; LEUKOCYTE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; CORNEA; CORNEAL TRANSPLANTATION; CYCLOSPORINE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE DELETION; GENE EXPRESSION; GENE SILENCING; GRAFT REJECTION; GRAFT SURVIVAL; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RANTES; RECEPTORS, CHEMOKINE; TRANSPLANTATION, HOMOLOGOUS;

EID: 34047252854     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1483     Document Type: Article

References (44)

1. Statistical Report 2000. Washington, DC: Eye Bank Association of America; 2000.
2. Council on Scientific Affairs. Report on the organ transplant panel: corneal transplantation. JAMA. 1988;259:719-722.
3. The Collaborative Corneal Transplantation Studies Research Group. The Collaborative Corneal Transplantation Studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110:1392-1403.
4. Mader TH, Stulting RD. The high-risk penetrating keratoplasty. Ophthalmol Clin North Am. 1991;4:411-426.
5. Foulks GN, Sanfilippo F. Beneficial effects of histocompatibility in high-risk corneal transplantation. Am J Ophthalmol. 1982;94:622-629.
6. Hamrah P, Djalilian AR, Stulting RD. Immunologically high-risk penetrating keratoplasty. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. 2nd ed. Vol. 2. St. Louis: Mosby; 2005:1619-1635.
7. Ing JJ, Ing HH, Nelson LR, Hodge DO, Bourne WM. Ten-year postoperative results of penetrating keratoplasty. Ophthalmology. 1998;105:1855-1865.
8. Raizman M. Corticosteroid therapy of eye disease; fifty years later. Arch Ophthalmol. 1996;114:1000-1001.
9. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenic rules of rejection do not apply. Transplantation. 1992;54:694-704.
10. Joo CK, Pepose JS, Stuart PM. T-cell mediated responses in a murine model of orthotopic corneal transplantation. Invest Ophthalmol Vis Sci. 1995;36:1530-1540.
11. Yamagami S, Miyazaki D, Ono SJ, Dana MR. Differential chemokine gene expression in corneal transplant rejection. Invest Ophthalmol Vis Sci. 1999;40:2892-2897.
12. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000;52:145-176.
13. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity. 1998;9:1-11.
14. Gao JL, Wynn TA, Chang Y, et al. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med. 1997;185:1959-1968.
15. Colantonio L, Iellem A, Clissi B, et al. Upregulation of integrin alphao/beta1 and chemokine receptor CCR1 by interleukin-12 promotes the migration of human type 1 helper T cells. Blood. 1999;94:2981-2989.
16. El-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol. 2002;14:562-568.
17. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardial allograft rejection. J Clin Invest. 2000;105:35-44.
18. Horuk R, Clayberger C, Krensky AM, et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem. 2001;6:4199-4204.
19. Horuk R, Shurey S, Ng HP, et al. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett. 2001;76:193-201.
20. Abdi R, Means TK, Ito T, et al. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol. 2004;172:767-775.
21. Hancock WW, Gao W, Csizmadia V, et al. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med. 2001;193:975-980.
22. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med. 2000;192:1515-1519.
23. Yun JJ, Fischbein MP, Laks H, et al. RANTES production during development of cardiac allograft vasculopathy. Transplantation. 2001;71:1649-1656.
24. Gao W, Faia K, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation. 2001;72:1199-1205.
25. Gerard C, Frossard JL, Bhatia M, et al. Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. J Clin Invest. 1997;100:2022-2027.
26. Yamagami S, Dana MR. The critical role of draining lymph nodes in corneal allosensitization. Invest Ophthalmol Vis Sci. 2001;42:1293-1298.
27. Hamrah P, Liu Y, Zhang Q, Dana MR. The corneal stroma is endowed with significant numbers of resident dendritic cells. Invest Ophthalmol Vis Sci. 2003;44:581-589.
28. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci. 2002;43:639-646.
29. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med. 2002;195:259-268.
30. Yamada J, Dana MR, Zhu SN, Alard P, Streilein JW. Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation. Arch Ophthalmol. 1998;116:1351-1357.
31. Yamada J, Streilein JW. Fate of orthotopic corneal allografts in C57BL/6 mice. Transpl Immunol. 1998;6:161-168.
32. Yamagami S, Hamrah P, Miyamoto K, et al. CCR5 chemokine receptor mediates recruitment of MHC-class II-positive Langerhans cells in the corneal epithelium. Invest Ophthalmol Vis Sci. 2005;46:1201-1207.
33. 3CR1) in cardiac allograft rejection. J Immunol. 2000;165:6067-6072.
34. Sato K, Kawasaki H, Nagayama H, et al. CC chemokine receptors, CCR-1 and CCR-3, are potentially involved in antigen-presenting cell function of human peripheral blood monocyte-derived dendritic cells. Blood. 1999;93:34-42.
35. Streilein JW. Immunobiology and immunopathology of corneal transplantation. Chem Immunol. 1999;73:186-206.
36. Huq S, Liu Y, Benichou G, Dana MR. Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment. J Immunol. 2004;173:4464-4469.
37. Niederkorn JY. The immune privilege of corneal allografts. Transplantation. 1999;67:1503-1508.
38. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18:593-620.
39. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2004;3:879-889.
40. Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology, emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea. 2000;19:625-643.
41. Eis V, Luckow B, Vielhauer V, et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15:337-347.
42. Novak N, Siepmann K, Zierhut M, Bieber T. The good, the bad and the ugly: APCs of the eye. Trends Immunol. 2003;24:570-574.
43. Hamrah P, Huq SO, Liu Y, Zhang Q, Dana MR. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. J Leukoc Biol. 2003;74:172-178.
44. Tumpey TM, Cheng H, Yan XT, Oakes JE, Lausch RN. Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. J Leukoc Biol. 1998;63:486-492.